Axsome Therapeutics, Inc. (LON:0HKF)

Market Cap	6.88B +72.3%
Revenue (ttm)	417.55M +65.8%
Net Income	-170.75M
EPS	-3.47
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70
Average Volume	269
Open	186.95
Previous Close	185.79
Day's Range	182.61 - 188.06
52-Week Range	88.21 - 193.51
Beta	0.43
RSI	59.11
Earnings Date	Feb 23, 2026

About Axsome Therapeutics

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 816
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HKF

Financial Performance

In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.

Financial numbers in USD